Prevalence of proteinuria among HIV-infected children attending a tertiary hospital in Lagos, Nigeria.
Sub-Saharan Africa is the epicentre of the HIV pandemic but there are few reports of HIV-related kidney diseases in children in this region. This study aimed to determine the prevalence of proteinuria in HIV-infected children at the Lagos University Teaching Hospital. Proteinuria was determined using urine protein-creatinine ratio. CD4+ cell count was determined for all the HIV-infected children. The mean age of the HIV-infected children was 74.4 +/- 35.6 months with a male: female ratio of 3:2. Compared with 6% of the 50 controls 20.5% of the 88 HIV-infected children had proteinuria (p = 0.026). Of 20 children with advanced clinical stage 40% had proteinuria compared with 14.7% of 68 children with milder stage (p = 0.004). Similarly, proteinuria was commoner among those with severe immunosuppression (p = 0.014). HAART use was not associated with significant difference in proteinuria prevalence (p = 0.491). Proteinuria was frequent among HIV-infected children, especially among those with advanced disease.
Esezobor
Christopher I
CI
Department of Paediatrics, Lagos University Teaching Hospital, Idi-Araba, Lagos State, Nigeria. esezobor@gmail.com
Iroha
Edna
E
Onifade
Elizabeth
E
Akinsulie
Adebola O
AO
Temiye
Edamisan O
EO
Ezeaka
Chinyere
C
D016263:AIDS-Associated Nephropathy / Q000453:epidemiology* / Q000209:etiology*; D000293:Adolescent; D019380:Anti-HIV Agents / Q000627:therapeutic use; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology*; D015497:HIV-1; D006784:Hospitals, Teaching; D006801:Humans; D007223:Infant; D007674:Kidney Diseases / Q000150:complications / Q000453:epidemiology; D008297:Male; D009549:Nigeria / Q000453:epidemiology; D015995:Prevalence; D011507:Proteinuria / Q000150:complications / Q000453:epidemiology* / Q000209:etiology*; D012307:Risk Factors; D016896:Treatment Outcome
D019380:Anti-HIV Agents